IceCure Medical Ltd.
corporate_fare Company Profile
IceCure Medical Ltd. (NASDAQ:ICCM) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 48 items for ICCM at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- FDA Approves IceCure's Post-Marketing Study Design for ProSense® Breast Cancer Treatment
- ASBrS Recommends Cryoablation for Low-Risk Breast Cancer, Boosting ProSense® Adoption
- IceCure Medical's ProSense® Cryoablation Proves Highly Effective for Breast Fibroadenomas in New Study
- IceCure Medical Completes 5-Year Follow-Up for ICESECRET Kidney Cancer Study; Final Analysis Expected Q2 2026
- IceCure Medical CFO Ronen Tsimmerman Resigns After Nine Years; Successor Search Underway
Financial Snapshot
Insider Transactions
ICCM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.